Although this study indicates that MEK inhibitors may have some benefit in the context of systemic immunotherapy for BTC, the modest increase in PFS observed probably reflects the additive effects of the individual therapies rather than a synergistic action resulting from MEK immunomodulation of the tumor microenvironment [67]. The gene discussed is MAP2K7; the disease is neoplasm.